Organization (Industry)
Pulmonx Corp
ClinicalTrials.gov lists Pulmonx Corp as lead sponsor of 13 trials. It has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Pulmonx Corp: 13 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (3)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Emphysema | 11 |
| Pulmonary Disease, Chronic Obstructive | 9 |
| Pulmonary Emphysema | 3 |
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2008 | 2 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Optimal Medical Management ( long acting beta agonist , long acting muscarinic antagonist and inhaled corticosteroids) | Emphysema | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 1 of 4 on time (n=4) |
Journals published in (22)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Respiration; international review of thoracic diseases | 6 |
| American journal of respiratory and critical care medicine | 5 |
| The New England journal of medicine | 4 |
| Chest | 3 |
| The European respiratory journal | 3 |
Showing 5 of 22 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 90 | 24 | 2025-12-30 |
SEC-reported annual financials (9)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 90,497,000 | -54,003,000 | 19,491,000 |
| 2024 | 83,789,000 | -56,394,000 | 17,570,000 |
| 2023 | 68,675,000 | -60,843,000 | 18,080,000 |
| 2022 | 53,662,000 | -58,923,000 | 15,397,000 |
| 2021 | 48,416,000 | -48,661,000 | 13,063,000 |
| 2020 | 32,733,000 | -32,231,000 | 7,460,000 |
| 2019 | 32,595,000 | -20,703,000 | 6,049,000 |
| 2018 | 20,004,000 | -18,479,000 | 6,991,000 |
| 2017 | not reported | not reported | not reported |
Financing and grant events (8)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-02 | Debt financing | 40,000,000 | Sec extracted |
| 2025-09-26 | Follow-on offering | 200,000,000 | Edgar offerings |
| 2023-02-21 | Debt financing | 20,000,000 | Sec extracted |
| 2022-11-03 | Other financing | not disclosed | Edgar offerings |
| 2022-10-31 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 8 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Zephyr Endobronchial Valve (EBV) 5.5-LP, REF: EBV-TS-5.5-LP | Class II | 2023-08-31 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| PULMONX, Corp. | Redwood City, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (117)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-02 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-03-02 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 117 events.
Biomarker capability evidence (30)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BLVRA | Trial sponsor | Named in trial inclusion criteria |
| MLIP | Trial sponsor | Named in trial inclusion criteria |
| BLVRA | Trial sponsor | Named in trial exclusion criteria |
| F2 | Trial sponsor | Named in trial exclusion criteria |
| F2 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 30 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, fda warning letters, fda untitled letters, fda import refusals, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.